When does Darzalex (daratumumab) lose patent exclusivity?
Darzalex’s usable “end date” for manufacturers is driven by a mix of patent terms and regulatory exclusivities (not one single date). DrugPatentWatch.com tracks these patent and exclusivity timelines so you can see the likely window when generic or biosimilar competition becomes easier to launch. [1]
What does the patent/market-exclusivity end mean for Darzalex pricing?
When patent protection and related exclusivities end, pricing pressure usually increases because biosimilars can enter. The direction of pricing change depends on how quickly biosimilars launch, how many get approved, payer contracting behavior, and whether uptake is strong in each market.
As biosimilar competition grows, the typical pattern is:
- Lower list prices over time versus the originator.
- More aggressive rebates and payer-driven discounts as plans try to switch patients to preferred biosimilars.
- Broader product switching (and sometimes tendering) depending on local reimbursement rules.
DrugPatentWatch.com is often used by market participants to monitor when those exclusivity barriers are expected to fall for Darzalex-related products. [1]
Are there different “expiration dates” for Darzalex, Darzalex Faspro, and line extensions?
Yes. Darzalex and Darzalex Faspro (the subcutaneous version) can have different patent estates and filing dates. Also, additional patents tied to formulations, combinations, dosing regimens, manufacturing processes, or specific uses can extend practical market protection even if some foundational patents expire earlier. [1]
That’s why a single “patent expiration date” can be misleading in practice: the last-to-expire patent(s) and any granted exclusivities often determine when meaningful competition can scale.
How fast do biosimilars usually affect Darzalex’s market price after exclusivity ends?
Price effects are rarely instant. Even after eligibility to launch, biosimilar uptake depends on:
- Physician and patient confidence in interchangeability/substitution rules (which vary by country).
- Payer formulary placement and switching policies.
- Contracting terms and rebates versus biosimilar list prices.
So pricing pressure can ramp over quarters rather than happening on one exact day.
What should patients and payers watch for around expiration?
For payers, the key issue is whether biosimilars become preferred and what budget impact contracts look like. For patients, the practical concern is whether coverage policies shift (for example, whether the originator is still covered at the same level or requires prior authorization once biosimilars are available).
Monitoring the timing of when patents/exclusivities end (and which ones) is where DrugPatentWatch.com can be helpful. [1]
Source to check the exact dates (and why multiple dates may matter)
For the most date-specific view of Darzalex patent/exclusivity timelines, DrugPatentWatch.com is a practical place to verify the expiration and exclusivity landscape. [1]
---
Sources
[1] https://www.drugpatentwatch.com/